We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMC
151
DELISTED
PharMerica Corporation
PMC
$226K 0.01%
+6,800
New +$209K
ICLR icon
152
Icon
ICLR
$13B
$225K 0.01%
3,348
+450
+16% +$30.4K
ENTA icon
153
Enanta Pharmaceuticals
ENTA
$410M
$223K 0.01%
+4,956
New +$193K
CAH icon
154
Cardinal Health
CAH
$55.3B
$215K 0.01%
2,574
– –
TARO
155
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$215K 0.01%
1,493
-32,081
-96% -$4.58M
SURG
156
DELISTED
SYNERGETICS USA, INC.
SURG
$208K 0.01%
44,266
+22,480
+103% +$109K
UNH icon
157
UnitedHealth
UNH
$356B
$206K 0.01%
+1,685
New +$199K
MOH icon
158
Molina Healthcare
MOH
$10.4B
$203K 0.01%
+2,888
New +$193K
MGLN
159
DELISTED
Magellan Health Services, Inc.
MGLN
$203K 0.01%
2,900
– –
DVCR
160
DELISTED
Diversicare Healthcare Services Inc
DVCR
$198K 0.01%
+15,337
New +$225K
EVFM
161
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$180K 0.01%
+222
New +$142K
ASND icon
162
Ascendis Pharma A/S
ASND
$16.6B
$176K 0.01%
10,000
– –
XIV
163
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
$162K 0.01%
+4,000
New +$171K
NVO
164
Novo Nordisk
NVO
$215B
$128K 0.01%
+4,680
New +$132K
NSPH
165
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$115K 0.01%
+35,379
New +$136K
DBVT
166
DBV Technologies
DBVT
$941M
$89K 0.01%
+300
New +$77.5K
MYGN icon
167
Myriad Genetics
MYGN
$305M
$85K 0.01%
+2,500
New +$85K
CAPR icon
168
Capricor Therapeutics
CAPR
$482M
$20K ﹤0.01%
400
– –
PCRX icon
169
Pacira BioSciences
PCRX
$1.02B
$4K ﹤0.01%
+50
New +$3.94K
AGEN
170
Agenus
AGEN
$376M
– –
-9,228
Closed -$929K
BIIB icon
171
Biogen
BIIB
$32.6B
– –
-18,200
Closed -$7.68M
BKD icon
172
Brookdale Senior Living
BKD
$2.91B
– –
-5,000
Closed -$189K
BLUE
173
DELISTED
bluebird bio
BLUE
– –
-10,422
Closed -$16.3M
CYTK icon
174
Cytokinetics
CYTK
$10.8B
– –
-30,227
Closed -$205K
DRRX
175
DELISTED
DURECT Corp
DRRX
– –
-90,706
Closed -$1.73M
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.